CCXI - ChemoCentryx Charts, Trade Ideas, Earnings, Ratings

TRENDING : Top 50 VXX (-5.93%) AAPL (%) SPY (0.87%) ROKU (-4.21%) QCOM (2.37%) PTON (-3.69%) ORMP (2.71%) NIO (0.45%) MRNS (-3.94%) MDB (-2.56%) M (2.53%) LTCUSD (%) JNCE (0.77%) HST (-0.28%) HIIQ (6.08%) FTSV (7.74%) FB (-2.73%) EXPR (1.63%) ETHUSD (%) EOSUSD (%) DLTR (1.15%) DGAZ (%) CVX (2.22%) CGIX (-0.6%) CGC (4.35%)

Up 5% to $33.61 today

CCXI - ChemoCentryx

$33.28 2.07[6.64%]

15 mins delayed data

People also watch : BIIB | JNJ | ABBV | BMY | PFE | FBIO

+Watchlist

3 StockHoot Traders following this.
Analyst Ratings | Earnings

Previous Close	$31.21	Open	$31.12
Volume	1.1M	Market Cap	685.55M
Yield		Last Dividend

Day

52 Week

Hedge Funds Dropped The Ball On ChemoCen...	12/11/19
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, ...

The Week Ahead In Biotech: ASH 2019 Gets...	12/01/19
Biotech stocks advanced in the holiday-shortened week, with upside driven mainly by the broader market strength. Reflecting the extreme volatility in ...

The Zacks Analyst Blog Highlights: Inter...	11/29/19
The Zacks Analyst Blog Highlights: Intercept, CymaBay, Amgen, Global Blood Therapeutics and ChemoCentryx

ChemoCentryx (CCXI) Upgraded to Buy: Wha...	11/28/19
ChemoCentryx (CCXI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

Company News For Nov 27, 2019	11/27/19
Companies In The News Are: TITN, HPE, SAFE, CCXI

Biotech Stock Roundup: CBAY Falls, CCXI ...	11/27/19
Key highlights of the past week include regulatory and pipeline updates.

ChemoCentryx Up on Encouraging Rare Dise...	11/27/19
ChemoCentryx (CCXI) announces positive data pivotal study evaluating its lead candidate, avacopan, in patients with ANCA vasculitis, a rare disease af...

The Daily Biotech Pulse: Tonix Says No S...	11/27/19
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 26) ...

Drug maker ChemoCentryx shares rocket on...	11/27/19
A set of conclusive findings from a late-stage clinical trial testing ChemoCentryx Inc.’s experimental vasculitis treatment surprised company executiv...

ChemoCentryx (CCXI) Stock Could Hit $40,...	11/26/19
ChemoCentryx (CCXI) is on everyone’s radar Tuesday, with shares flying higher by more than 350% at one point. The ride was instigated by the positive ...

Benzinga Pro's Top 5 Stocks To Watch For...	11/26/19
Benzinga Pro's Stocks To Watch For Tuesday Best Buy (BBY) - Reported strong Q3 results, Q4 guidance and raised FY20 guidance. Shares were up 4% follow...

ANALYST RATINGS

3 analyst ratings (Last 6 months)

66.67 %

Strong Buy + Buy

Price Target (PT)

rating	11/26/19
Raymond James maintains Strong Buy rating and raises Price Target from $17.00 to $56.00

Buy rating	11/26/19
Canaccord Genuity maintains Buy rating and raises Price Target from $16.00 to $48.00

Strong Buy rating	09/12/19
JP Morgan upgrades from Neutral to Overweight rating and lowers Price Target from $16.00 to $14.00

EARNINGS

Date	2019-11-04 (AMC)	Est. (EPS/Rev.)	($0.28)/ 7.7M
Actual (EPS/Rev.)	$-0.22/ $10.58 M	EPS (TTM)	0

TRADERS TRACKING $CCXI

Service Name	Trader	% Success
Tech Trades	Ravi	90.00 %	Follow
Momentum Trading	j sal	33.00 %	Follow

SHOW ALL TRADERS

About Us

Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.

Product Types

Strategies

Follow Us

Secure Payments

We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.